[go: up one dir, main page]

MA26790A1 - Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie - Google Patents

Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie

Info

Publication number
MA26790A1
MA26790A1 MA26402A MA26402A MA26790A1 MA 26790 A1 MA26790 A1 MA 26790A1 MA 26402 A MA26402 A MA 26402A MA 26402 A MA26402 A MA 26402A MA 26790 A1 MA26790 A1 MA 26790A1
Authority
MA
Morocco
Prior art keywords
oxaluria
dietetic
hyper
prevention
treatment
Prior art date
Application number
MA26402A
Other languages
English (en)
Inventor
Simone Claudio De
Original Assignee
Vsl Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vsl Pharma Ltd filed Critical Vsl Pharma Ltd
Publication of MA26790A1 publication Critical patent/MA26790A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MA26402A 1999-05-28 2001-11-08 Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie MA26790A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000338A IT1309427B1 (it) 1999-05-28 1999-05-28 Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso

Publications (1)

Publication Number Publication Date
MA26790A1 true MA26790A1 (fr) 2004-12-20

Family

ID=11406789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26402A MA26790A1 (fr) 1999-05-28 2001-11-08 Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie

Country Status (34)

Country Link
US (2) US6562336B2 (fr)
EP (1) EP1181027B1 (fr)
JP (1) JP4737836B2 (fr)
KR (1) KR100781703B1 (fr)
CN (1) CN100350919C (fr)
AR (1) AR024555A1 (fr)
AT (1) ATE265857T1 (fr)
AU (1) AU773459B2 (fr)
BR (1) BR0011038B1 (fr)
CA (1) CA2373255C (fr)
CZ (1) CZ20014076A3 (fr)
DE (1) DE60010456T2 (fr)
DK (1) DK1181027T3 (fr)
DZ (1) DZ3165A1 (fr)
EA (1) EA004257B1 (fr)
EE (1) EE200100618A (fr)
ES (1) ES2219344T3 (fr)
HK (1) HK1048066B (fr)
HU (1) HU225134B1 (fr)
IL (3) IL146703A0 (fr)
IS (1) IS6150A (fr)
IT (1) IT1309427B1 (fr)
MA (1) MA26790A1 (fr)
MX (1) MXPA01012184A (fr)
NO (1) NO20015782L (fr)
NZ (1) NZ516020A (fr)
PL (1) PL352014A1 (fr)
PT (1) PT1181027E (fr)
SI (1) SI1181027T1 (fr)
SK (1) SK16612001A3 (fr)
TR (1) TR200103439T2 (fr)
UA (1) UA71621C2 (fr)
WO (1) WO2000072855A2 (fr)
ZA (1) ZA200110504B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US9655932B2 (en) 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
WO2004112809A1 (fr) * 2003-06-24 2004-12-29 Otsuka Pharmaceutical Co., Ltd. Composition pour diminuer le taux d'acide urique serique
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
JP2007529214A (ja) * 2004-03-19 2007-10-25 ダニスコ エイ／エス ショートニング用乳化剤組成物
US7468182B2 (en) * 2004-10-27 2008-12-23 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
EP2261323A1 (fr) 2005-05-31 2010-12-15 The Iams Company Lactobacilles probiotiques félins
PL1962873T3 (pl) 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
CN104013581A (zh) * 2005-12-16 2014-09-03 奥克斯赛拉公司 用于减少草酸和/或其盐的组合物和方法
KR20090109131A (ko) * 2007-03-27 2009-10-19 더 프록터 앤드 갬블 캄파니 생균제를 투여하기 위한 방법 및 키트
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
JP5632289B2 (ja) 2008-09-30 2014-11-26 株式会社明治 高いシュウ酸分解能を有する乳酸菌
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
ITMI20121173A1 (it) * 2012-07-04 2014-01-05 Neupharma Srl Composizioni dietetiche e/o farmaceutiche comprendenti ceppi di lactobacillus e bifidobacterium capaci di degradare gli ossalati e di indurre una risposta immunitaria di tipo anti-infiammatorio
ITMI20130795A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici e/o bifidobatteri per uso nel trattamento preventivo e/o curativo delle infezioni batteriche e/o delle infiammazioni del tratto urinario e/o della prostata che sono la causa di prostatiti e ipertrofia prostat
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
JP5765832B2 (ja) * 2013-12-26 2015-08-19 雪印メグミルク株式会社 加齢に伴う代謝異常症の予防・改善・治療剤
ES2808677T3 (es) * 2014-10-01 2021-03-01 Triphase Pharmaceuticals Pvt Ltd Cepas termoestables, productos y métodos de las mismas
ITUB20155752A1 (it) * 2015-11-19 2017-05-19 Probiotical Spa Composizione di batteri per uso per attenuare le diminuzioni di prestazione dopo un esercizio fisico che danneggia i muscoli.
CN107868776A (zh) 2016-09-23 2018-04-03 武汉康复得生物科技股份有限公司 糖基化草酸脱羧酶及其制备和应用
WO2018125735A1 (fr) 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition et procédé pour maintenir une fonction rénale saine
WO2020123483A1 (fr) * 2018-12-10 2020-06-18 Novome Biotechnologies, Inc. Méthodes et compositions pour le traitement de l'hyperoxalurie
CN113308416B (zh) * 2021-07-20 2023-02-24 四川大学 一株具有抑制肾结石形成能力的植物乳杆菌及其应用
CN115851508B (zh) * 2022-10-13 2024-01-09 山东中科嘉亿生物工程有限公司 一种降草酸、改善肾结石的嗜热链球菌jyst-26及其产品、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810520A (ja) * 1981-07-10 1983-01-21 Miyarisan Kk 胆石症の治療薬
DE69219768T2 (de) * 1992-07-06 1997-08-28 Societe Des Produits Nestle S.A., Vevey Milchbakterien
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
ATE169456T1 (de) * 1996-12-23 1998-08-15 Sitia Yomo Spa Lyophilisierte, lebende bakerien enthaltende nahrungszusammensetzung
JP4996780B2 (ja) * 1997-05-23 2012-08-08 オクセラ インコーポレイテッド シュウ酸塩関連疾患を予防するためのシュウ酸塩分解微生物またはシュウ酸塩分解酵素
RU2139346C1 (ru) * 1999-03-02 1999-10-10 Шендеров Борис Аркадьевич Штамм бактерий lactobacillus plantarum, обладающий способностью снижать уровень оксалата и используемый для приготовления препаратов и продуктов питания для профилактики и лечения гипероксалурии

Also Published As

Publication number Publication date
AR024555A1 (es) 2002-10-16
ZA200110504B (en) 2002-09-25
DK1181027T3 (da) 2004-08-16
US20020061292A1 (en) 2002-05-23
IL199437A (en) 2016-10-31
SK16612001A3 (sk) 2002-04-04
HK1048066A1 (en) 2003-03-21
TR200103439T2 (tr) 2002-06-21
AU773459B2 (en) 2004-05-27
PL352014A1 (en) 2003-07-14
CA2373255C (fr) 2010-01-19
HK1048066B (zh) 2008-08-01
ITRM990338A1 (it) 2000-11-28
IL146703A (en) 2010-03-28
DE60010456D1 (de) 2004-06-09
USRE39585E1 (en) 2007-04-24
CZ20014076A3 (cs) 2002-03-13
HU225134B1 (en) 2006-06-28
IL146703A0 (en) 2002-07-25
CN100350919C (zh) 2007-11-28
CN1365284A (zh) 2002-08-21
NO20015782L (no) 2002-01-25
CA2373255A1 (fr) 2000-12-07
KR20020019918A (ko) 2002-03-13
DZ3165A1 (fr) 2000-12-07
JP2003500451A (ja) 2003-01-07
BR0011038A (pt) 2002-02-26
HUP0201409A2 (en) 2002-08-28
DE60010456T2 (de) 2005-05-12
ITRM990338A0 (it) 1999-05-28
AU5101600A (en) 2000-12-18
IT1309427B1 (it) 2002-01-23
IL199437A0 (en) 2011-07-31
BR0011038B1 (pt) 2014-02-18
HUP0201409A3 (en) 2004-10-28
MXPA01012184A (es) 2003-06-30
US6562336B2 (en) 2003-05-13
NO20015782D0 (no) 2001-11-27
ATE265857T1 (de) 2004-05-15
JP4737836B2 (ja) 2011-08-03
NZ516020A (en) 2003-06-30
EA200101262A1 (ru) 2002-04-25
UA71621C2 (en) 2004-12-15
WO2000072855A2 (fr) 2000-12-07
EA004257B1 (ru) 2004-02-26
WO2000072855A3 (fr) 2001-06-28
EP1181027A2 (fr) 2002-02-27
KR100781703B1 (ko) 2007-12-03
IS6150A (is) 2001-11-08
EP1181027B1 (fr) 2004-05-06
PT1181027E (pt) 2004-09-30
SI1181027T1 (en) 2004-08-31
ES2219344T3 (es) 2004-12-01
EE200100618A (et) 2003-02-17

Similar Documents

Publication Publication Date Title
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
IL205298A0 (en) Pharmaceutical compositions comprising an antibody to ab and uses thereof in the prevention or treatment of a disease characterized by amyloid deposit
HUP0103654A2 (hu) Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DZ2675A1 (fr) Association pharmaceutique pour le traitement d'undysfunctionnement sexuel et compositions la conte nant.
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2742657B1 (fr) Compositions pour le traitement des matieres keratiniques contenant l'association d'un polymere polyampholyte et d'un polymere cationique
FR2792835B3 (fr) Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2741355B1 (fr) Composition pour le traitement d'objets que l'on souhaite nettoyer et/ou desinfecter
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
FR2744361B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
EP0990441A4 (fr) Medicament pour le traitement de la nephropathie diabetique
FR2792199B3 (fr) Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
FR2720944B1 (fr) Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie.